A a glycoprotein IIb/IIIa receptor antagonist
A Chimeric monoclonal antibody which inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor and other adhesive molecules to GP IIb/IIIa receptor sites on activated platelets. Free plasma concentration of the drug decreases rapidly with an initial half life of <10 min. and a second phase half life of 30 minutes. Platelet function recovers over the course of 48 hours.
A Chimeric monoclonal antibody which inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor and other adhesive molecules to GP IIb/IIIa receptor sites on activated platelets. Free plasma concentration of the drug decreases rapidly with an initial half life of <10 min. and a second phase half life of 30 minutes. Platelet function recovers over the course of 48 hours.
© 2025[current_year] The Doctors Platform. All Right Reserved.
© 2025 The Doctors Platform. All Right Reserved.
